MetaCap

Revolution Medicines Inc. (RVMD)

NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

161.20+1.77 (+1.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RVMD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$34.87B
EPS (TTM)
-$9.13
52-week range
71.15 – 224.31
Day range
160.22 – 169.51
Volume / Avg
4.74M / 2.28M
Beta
—

52-week range

$71.15$224.31

RVMD stock today

Shares of Revolution Medicines (RVMD) finished higher on Nov 20 at $161.20, a gain of 1.11% or $1.77 per share, versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 4.74M shares, a sign of unusually heavy trading. Shares are 28.1% below their 52-week high of $224.31, set on Aug 27, 2026 and 126.6% above the 52-week low of $71.15, in the middle of the past year's range.

RVMD is up 102.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 127.5%. Revolution Medicines has posted a net loss over the last twelve months (EPS of -$9.13), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Revolution Medicines

Company profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Mark A. Goldsmith M.D., Ph.D.
Headquarters
Redwood City, CA
Employees
883
IPO year
2020
Website
revmed.com

Financial highlights

Full financials

In fiscal 2025, Revolution Medicines generated $0 in revenue, up 0.0% from fiscal 2024. Revolution Medicines reported a net loss of $1.13 billion, compared with a loss of $600.1 million a year earlier. Diluted earnings per share came in at -$5.95.

Revolution Medicines annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$11.58M$35.38M$29.39M
Growth—-100.00%-67.27%+20.38%-31.62%
Net income$-1.13B$-600.09M$-436.37M$-248.71M$-187.09M
EPS (diluted)$-5.95$-3.58$-3.86$-3.08$-2.57

Analyst forecast

Forecast

Consensus (24 analysts)

strong_buy

Avg. price target

$274.68+70.40%

  • Strong buy 5
  • Buy 18
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $179.00High $350.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.90 vs $-2.34
Surprise
+18.80%

RVMD news

All RVMD news

Revolution Medicines peers

Health Care sector
RVMD peer companies
CompanyPrice% ChgMarket capCompare
BIIBBiogen Inc.249.59+1.00%$36.89Bvs RVMD
BNTXBioNTech SE ADR80.96-0.52%$20.07Bvs RVMD
EXELExelixis Inc.64.63-1.82%$15.77Bvs RVMD
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs RVMD
TECHBio-Techne Corp72.67-0.04%$11.42Bvs RVMD
ARGXargenx SE ADR925.70-1.73%$58.21Bvs RVMD
RGENRepligen Corporation163.81-3.81%$10.47Bvs RVMD
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs RVMD

Indexes, lists and sector

Revolution Medicines stock FAQ

What is Revolution Medicines's stock price today?

RVMD last traded at $161.20 as of Nov 20, 4:00 PM EST, up 1.11% on the day. Prices are delayed at least 15 minutes.

Who is Revolution Medicines's CEO?

Dr. Mark A. Goldsmith M.D., Ph.D. is the chief executive officer of Revolution Medicines Inc., which has about 883 employees.

What is the RVMD 52-week high?

The 52-week high for RVMD is $224.31 and the 52-week low is $71.15. The stock is currently 28.1% below its high.

Compare RVMD